George Coukos

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


405 publications

En préparation
 
Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma
Barras David, Ghisoni Eleonora, Chiffelle Johanna, Orcurto Angela, Dagher Julien, Fahr Noémie, Benedetti Fabrizio, Crespo Isaac, Zimmermann Stefan, Duran Rafael et al., this Pre print is under peer review in Science Immunology.
[DOI][serval:BIB_097A733AD4EC]
Sous presse
 
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.
Huber F., Arnaud M., Stevenson B.J., Michaux J., Benedetti F., Thevenet J., Bobisse S., Chiffelle J., Gehert T., Müller M. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14DC47CDBB48]
 
Patient-derived mini-colons enable long-term modeling of tumor-microenvironment complexity.
Lorenzo-Martín L.F., Broguiere N., Langer J., Tillard L., Nikolaev M., Coukos G., Homicsko K., Lutolf M.P. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6FBB2EBCBF0E]
 
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88A45E78E09C]
 
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF334A302D27]
2024
 
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.
Ghisoni E., Morotti M., Sarivalasis A., Grimm A.J., Kandalaft L., Laniti D.D., Coukos G., 2024/11. Nature reviews. Clinical oncology, 21 (11) pp. 801-817. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A4CCCAE3C462]
 
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
Martín-Lluesma S., Svane I.M., Dafni U., Vervita K., Karlis D., Dimopoulou G., Tsourti Z., Rohaan M.W., Haanen JBAG, Coukos G., 2024/10. Annals of oncology, 35 (10) pp. 860-872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C3B84E4D1FD]
 
Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.
Perez MAS, Chiffelle J., Bobisse S., Mayol-Rullan F., Bugnon M., Bragina M.E., Arnaud M., Sauvage C., Barras D., Laniti D.D. et al., 2024/10. Advanced science, 11 (40) pp. e2405949. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0C9B82A244FB]
 
Nanoplasmonic Single-Tumoroid Microarray for Real-Time Secretion Analysis.
Liu Y.C., Ansaryan S., Tan J., Broguiere N., Lorenzo-Martín L.F., Homicsko K., Coukos G., Lütolf M.P., Altug H., 2024/09. Advanced science, 11 (34) pp. e2401539. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_854452266478]
 
Probing the killing potency of tumor-infiltrating lymphocytes on microarrayed colorectal cancer tumoroids.
Dutta D., Lorenzo-Martín L.F., Rivest F., Broguiere N., Tillard L., Ragusa S., Brandenberg N., Höhnel S., Saugy D., Rusakiewicz S. et al., 2024/08/14. NPJ precision oncology, 8 (1) p. 179. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7156FDC43C39]
 
Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage.
Lotze M.T., Maeurer M., Quezada S.A., Coukos G., 2024/08/02. Cancer discovery, 14 (8) pp. 1366-1368. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E6DAC6C7BDC7]
Reflections on the opportunities and challenges of applying experience-based co-design (EBCD) to phase 1 clinical trials in oncology.
Graber N., Canova N., Bryant-Lukosius D., Robert G., Navarro-Rodrigo B., Trueb L., Coukos G., Eicher M., Corbière T., Colomer-Lahiguera S., 2024/08. Health expectations, 27 (4) pp. e14068. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6336B72F30FA]
Urolithin-A Promotes CD8+ T Cell-mediated Cancer Immunosurveillance via FOXO1 Activation.
Ginefra P., Hope H.C., Chiang Y.H., Nutten S., Blum S., Coukos G., Vannini N., 2024/05/03. Cancer research communications, 4 (5) pp. 1189-1198. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A155196AF6D3]
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al., 2024/05. Nature, 629 (8011) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5FCB44D6E4AA]
Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
Stefanidis E., Semilietof A., Pujol J., Seijo B., Scholten K., Zoete V., Michielin O., Sandaltzopoulos R., Coukos G., Irving M., 2024/04/23. The Journal of clinical investigation, 134 (11). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_36EE50DF7CA8]
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N., Fortis E., Spathis A., Anastasiou M., Economopoulou P., Foukas GRP, Lelegiannis I.M., Rusakiewicz S., Vathiotis I., Aung T.N. et al., 2024/04. Annals of oncology, 35 (4) pp. 340-350. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_77EE6FBCAC5B]
 
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S., Tyekucheva S., Tissot-Renaud S., Chaba K., Imbimbo M., Benedetti F., Kammler R., Hornfeld J., Munzone E., Gianni L. et al., 2024/03. European journal of cancer, 200 p. 113535. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DE560AF185F]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M., Huber F., Arnaud M., Kraemer A.I., Altimiras E.R., Michaux J., Taillandier-Coindard M., Chiffelle J., Murgues B., Gehret T. et al., 2023/11/14. Immunity, 56 (11) pp. 2650-2663.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_809F4EAB21AB]
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
Tillé L., Cropp D., Charmoy M., Reichenbach P., Andreatta M., Wyss T., Bodley G., Crespo I., Nassiri S., Lourenco J. et al., 2023/10. Nature immunology, 24 (10) pp. 1645-1653. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B944FAF7B77]
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03AE420D2700]
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Reichenbach P., Giordano Attianese GMP, Ouchen K., Cribioli E., Triboulet M., Ash S., Saillard M., Vuillefroy de Silly R., Coukos G., Irving M., 2023/09. Nature biomedical engineering, 7 (9) pp. 1063-1080. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_22CADB5FE4EC]
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
Racle J., Guillaume P., Schmidt J., Michaux J., Larabi A., Lau K., Perez MAS, Croce G., Genolet R., Coukos G. et al., 2023/06/13. Immunity, 56 (6) pp. 1359-1375.e13. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9BA5A00EAA19]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
 
Generation of a novel synthetic CD8<sup>+</sup> T cell state that leads to tumor control in mice.
Corria-Osorio J., Coukos G., 2023/05. Nature immunology, 24 (5) pp. 755-756. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B121C8D85A4]
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
Corria-Osorio J., Carmona S.J., Stefanidis E., Andreatta M., Ortiz-Miranda Y., Muller T., Rota I.A., Crespo I., Seijo B., Castro W. et al., 2023/05. Nature immunology, 24 (5) pp. 869-883. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6529135A8DD]
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
Kraemer A.I., Chong C., Huber F., Pak H., Stevenson B.J., Müller M., Michaux J., Altimiras E.R., Rusakiewicz S., Simó-Riudalbas L. et al., 2023/05. Nature cancer, 4 (5) pp. 608-628. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AFB188A208B6]
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC23FF064822]
 
A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism.
Maric T., Bazhin A., Khodakivskyi P., Mikhaylov G., Solodnikova E., Yevtodiyenko A., Giordano Attianese GMP, Coukos G., Irving M., Joffraud M. et al., 2023/01/15. Biosensors & bioelectronics, 220 p. 114826. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C15EADDDA9C7]
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells.
Arnaud M., Coukos G., Harari A., 2023/01. Clinical and translational medicine, 13 (1) pp. e1174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_803001E6E3E3]
2022
 
Genetics and anatomy sculpt immune-cell partners of ovarian cancer
Dangaj Laniti Denarda, Coukos George, 2022/12/22. Nature, 612 (7941) pp. 634-636. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01D5FAC4C129]
 
TIL Therapy Entering the Mainstream.
Coukos G., 2022/12/08. The New England journal of medicine, 387 (23) pp. 2185-2186. Peer-reviewed.
[DOI][Pmid][serval:BIB_0B993D925FDD]
 
IL-2 engineered MSCs rescue T cells in tumours.
Irving M., Ortiz-Miranda Y., Coukos G., 2022/12. Nature cell biology, 24 (12) pp. 1689-1691. Peer-reviewed.
[DOI][Pmid][serval:BIB_A1B1B8C4A855]
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap.
Ghisoni E., Morotti M., Colomer-Lahiguera S., Eicher M., Coukos G., Trueb L., Di Maio M., 2022/12. Journal for immunotherapy of cancer, 10 (12) pp. e006082. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E61BEAAE8B5E]
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF494F840FDA]
 
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
Kandalaft L.E., Dangaj Laniti D., Coukos G., 2022/11. Nature reviews. Cancer, 22 (11) pp. 640-656. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B0D5013539C]
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
Ochoa-de-Olza M., Bourhis J., Coukos G., Herrera F.G., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004939. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DBBB9D3370A5]
Deciphering the landscape of phosphorylated HLA-II ligands.
Solleder M., Racle J., Guillaume P., Coukos G., Bassani-Sternberg M., Gfeller D., 2022/05/20. iScience, 25 (5) p. 104215. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_54BD67DD87D2]
 
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Digklia A., Coukos G., Homicsko K., 2022/05/02. Clinical cancer research, 28 (9) pp. 1745-1747. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0CAC463D4200]
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
Ochoa-de-Olza M., Bourhis J., Coukos G., Herrera F.G., 2022/04. The Lancet. Oncology, 23 (4) pp. e157. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BC56553604E1]
 
Lighting up the tumor fire with low-dose irradiation.
Herrera F.G., Romero P., Coukos G., 2022/03. Trends in immunology, 43 (3) pp. 173-179. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49751A0F49EB]
 
Identification of tumor antigens with immunopeptidomics.
Chong C., Coukos G., Bassani-Sternberg M., 2022/02. Nature biotechnology, 40 (2) pp. 175-188. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0938B9EC9DC3]
 
High-Throughput Single-Cell TCR-pMHC Dissociation Rate Measurements Performed by an Autonomous Microfluidic Cellular Processing Unit.
Jammes F., Schmidt J., Coukos G., Maerkl S.J., 2022/01/28. ACS sensors, 7 (1) pp. 159-165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3E11871D7007]
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
Fierle J.K., Abram-Saliba J., Atsaves V., Brioschi M., de Tiani M., Reichenbach P., Irving M., Coukos G., Dunn S.M., 2022/01/21. Scientific reports, 12 (1) p. 1136. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D41964E1822]
 
A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
Irving M., Zoete V., Bassani-Sternberg M., Coukos G., 2022/01/10. Cancer cell, 40 (1) pp. 20-22. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FF0839215AF4]
 
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma.
Mohsen M.O., Speiser D.E., Michaux J., Pak H., Stevenson B.J., Vogel M., Inchakalody V.P., de Brot S., Dermime S., Coukos G. et al., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e002927. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C41D094CADC7]
 
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.
Cribioli E., Giordano Attianese GMP, Coukos G., Irving M., 2022. Frontiers in immunology, 13 p. 951143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BEC9380646B]
 
Enforcing GLUT3 expression in CD8+ T cells improves fitness and tumor control by promoting glucose uptake and energy storage
Cribioli E., Giordano Attianese GMP, Ginefra P., Signorino-Gelo A., Vuillefroy de Silly R., Vannini N., Hess C., Irving M., Coukos G., 2022. Frontiers in immunology, 13 p. 976628. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3101020C948F]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
Matthaiou E.I., Guo Y., Barar J., Sandaltzopoulos R., Kandalaft L.E., Li C., Coukos G., Omidi Y., 2022. BioImpacts, 12 (1) pp. 65-86. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7205BBE80A2D]
2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope.
Ebrahimi-Nik H., Moussa M., Englander R.P., Singhaviranon S., Michaux J., Pak H., Miyadera H., Corwin W.L., Keller GLJ, Hagymasi A.T. et al., 2021/11/05. Nature communications, 12 (1) p. 6423. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_63F82E17F0C1]
Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays.
Duchamp M., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2021/09/06. Micromachines, 12 (9) p. 1076. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_550F1A17928D]
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle J.K., Brioschi M., de Tiani M., Wetterwald L., Atsaves V., Abram-Saliba J., Petrova T.V., Coukos G., Dunn S.M., 2021/08/17. Cell reports. Medicine, 2 (8) p. 100362. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3930B2D62A38]
Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease.
Dietz M., Kamani C.H., Deshayes E., Dunet V., Mitsakis P., Coukos G., Nicod Lalonde M., Schaefer N., Prior J.O., 2021/08/14. EJNMMI research, 11 (1) p. 71. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BC418C20751B]
 
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G. et al., 2021/08. Journal for immunotherapy of cancer, 9 (8) pp. e002151. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B098C62EF15]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
Interpretation of T cell states from single-cell transcriptomics data using reference atlases.
Andreatta M., Corria-Osorio J., Müller S., Cubas R., Coukos G., Carmona S.J., 2021/05/20. Nature communications, 12 (1) p. 2965. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BE1D257DF142]
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A. et al., 2021/05/04. NPJ vaccines, 6 (1) p. 68. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2126872FC2DC]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A. et al., 2021/03/15. NPJ vaccines, 6 (1) p. 36. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8E270F9DEDE8]
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
Mampuya W.A., Bouchaab H., Schaefer N., Kinj R., La Rosa S., Letovanec I., Ozsahin M., Bourhis J., Coukos G., Peters S. et al., 2021/03. Clinical and translational radiation oncology, 27 pp. 85-88. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C82F89BA6EDB]
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig U.F., Majjigapu S.R., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P. et al., 2021/02/25. Journal of medicinal chemistry, 64 (4) pp. 2205-2227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FC8F8F2B6EC]
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
Schmidt J., Smith A.R., Magnin M., Racle J., Devlin J.R., Bobisse S., Cesbron J., Bonnet V., Carmona S.J., Huber F. et al., 2021/02/16. Cell reports. Medicine, 2 (2) p. 100194. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9AA90BD897A9]
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Lanitis E., Rota G., Kosti P., Ronet C., Spill A., Seijo B., Romero P., Dangaj D., Coukos G., Irving M., 2021/02/01. The Journal of experimental medicine, 218 (2) pp. e20192203. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_75DE24FE756B]
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Cachot A., Bilous M., Liu Y.C., Li X., Saillard M., Cenerenti M., Rockinger G.A., Wyss T., Guillaume P., Schmidt J. et al., 2021/02. Science advances, 7 (9) pp. eabe3348. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FDE10B2A046]
Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model.
Delage J.A., Faivre-Chauvet A., Barbet J., Fierle J.K., Schaefer N., Coukos G., Viertl D., Dunn S.M., Gnesin S., Prior J.O., 2021/01/13. Pharmaceutics, 13 (1) p. 96. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_28C0A40301A0]
 
Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
D'Onofrio A., Gano L., Melo R., Mendes F., Oliveira M.C., Denoël T., Schaefer N., Viertl D., Fierle J., Coukos G. et al., 2021/01. European journal of pharmaceutics and biopharmaceutics, 158 pp. 233-244. Peer-reviewed.
[DOI][Pmid][serval:BIB_95FD98ADDB6D]
Cell therapies in ovarian cancer.
Sarivalasis A., Morotti M., Mulvey A., Imbimbo M., Coukos G., 2021. Therapeutic advances in medical oncology, 13 p. 17588359211008399. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10D5AD530F84]
 
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Dafni U., Martín-Lluesma S., Balint K., Tsourti Z., Vervita K., Chenal J., Coukos G., Zaman K., Sarivalasis A., Kandalaft L.E., 2021/01. European journal of cancer, 142 pp. 63-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D084831A838B]
Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
Pak H., Michaux J., Huber F., Chong C., Stevenson B.J., Müller M., Coukos G., Bassani-Sternberg M., 2021. Molecular & cellular proteomics, 20 p. 100080. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCFCF966CE50]
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Baumgaertner P., Sankar M., Herrera F.G, Benedetti F., Barras D., Thierry A.C., Dangaj D., Kandalaft L.E., Coukos G., Xenarios I. et al., 2021. Frontiers in immunology, 12 p. 633910. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E707FFE34C52]
2020
 
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T. et al., 2020/12. Cytotherapy, 22 (12) pp. 780-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30851676B0A7]
 
Disturbed mitochondrial dynamics in CD8<sup>+</sup> TILs reinforce T cell exhaustion.
Yu Y.R., Imrichova H., Wang H., Chao T., Xiao Z., Gao M., Rincon-Restrepo M., Franco F., Genolet R., Cheng W.C. et al., 2020/12. Nature immunology, 21 (12) pp. 1540-1551. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89908ED24FA7]
Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes
Chong Chloe, Müller Markus, Pak HuiSong, Harnett Dermot, Huber Florian, Grun Delphine, Leleu Marion, Auger Aymeric, Arnaud Marion, Stevenson Brian J. et al., 2020/12. Nature Communications, 11 (1). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_03EA897A1141]
 
Structural dissimilarity from self drives neoepitope escape from immune tolerance.
Devlin J.R., Alonso J.A., Ayres C.M., Keller GLJ, Bobisse S., Vander Kooi C.W., Coukos G., Gfeller D., Harari A., Baker B.M., 2020/11. Nature chemical biology, 16 (11) pp. 1269-1276. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_186F0AD1C570]
 
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Wells D.K., van Buuren M.M., Dang K.K., Hubbard-Lucey V.M., Sheehan KCF, Campbell K.M., Lamb A., Ward J.P., Sidney J., Blazquez A.B. et al., 2020/10/29. Cell, 183 (3) pp. 818-834.e13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F6095670EC38]
 
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.
Lanitis E., Coukos G., Irving M., 2020/10. Current opinion in biotechnology, 65 pp. 75-87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97CF39EFF89C]
 
Biotechnologies to tackle the challenge of neoantigen identification.
Arnaud M., Duchamp M., Bobisse S., Renaud P., Coukos G., Harari A., 2020/10. Current opinion in biotechnology, 65 pp. 52-59. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_78FA51F85D77]
High versus low dose irradiation for tumor immune reprogramming.
de Olza M.O., Bourhis J., Irving M., Coukos G., Herrera F.G., 2020/10. Current opinion in biotechnology, 65 pp. 268-283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_330632946BBD]
T-cell repertoire analysis and metrics of diversity and clonality.
Chiffelle J., Genolet R., Perez M.A., Coukos G., Zoete V., Harari A., 2020/10. Current opinion in biotechnology, 65 pp. 284-295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_598F3EDCA20B]
Mineral and Amino Acid Profiling of Different Hematopoietic Populations from the Mouse Bone Marrow.
Girotra M., Monnard C., Konz T., Sizzano F., Goulet L., Godin J.P., Coukos G., Rezzi S., Vannini N., 2020/09/03. International journal of molecular sciences, 21 (17) p. 6444. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_477EEDC014A0]
 
High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays.
Brandenberg N., Hoehnel S., Kuttler F., Homicsko K., Ceroni C., Ringel T., Gjorevski N., Schwank G., Coukos G., Turcatti G. et al., 2020/09. Nature biomedical engineering, 4 (9) pp. 863-874. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71E34713FAA0]
 
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.
Ochoa de Olza M., Navarro Rodrigo B., Zimmermann S., Coukos G., 2020/09. The Lancet. Oncology, 21 (9) pp. e419-e430. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_208B57498352]
 
177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma
Delage J.A., Faivre-Chauvet A., Fierle J.K., Gnesin S., Schaefer N., Coukos G., Dunn S.M., Viertl D., Prior J.O., 2020/08/17. EJNMMI research, 10 (1) p. 98. Peer-reviewed.
[DOI][Pmid][serval:BIB_4E04534CDA56]
 
Correction to: Preclinical Evaluation and Dosimetry of [111In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)
Cicone Francesco, Denoël Thibaut, Gnesin Silvano, Riggi Nicolo, Irving Melita, Jakka Gopinadh, Schaefer Niklaus, Viertl David, Coukos George, Prior John O., 2020/08. 1.
[DOI][WoS][Pmid][serval:BIB_81A7D3CC3803]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1).
Cicone F., Denoël T., Gnesin S., Riggi N., Irving M., Jakka G., Schaefer N., Viertl D., Coukos G., Prior J.O., 2020/08. Molecular imaging and biology, 22 (4) pp. 979-991. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813B48F40C5F]
 
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams S.F., Grimm A.J., Chiang C.L., Mookerjee A., Flies D., Jean S., McCann G.A., Michaux J., Pak H., Huber F. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e000875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B7CF92C7BCB]
 
Multielemental Analysis of Low-Volume Samples Reveals Cancer-Specific Profile in Serum and Sorted Immune Cells
Konz Tobias, Monnard Caroline, Restrepo Marcela Rincon, Laval Julie, Sizzano Federico, Girotra Mukul, Dammone Gabriele, Palini Alessio, Coukos George, Rezzi Serge et al., 2020/07/07. Analytical Chemistry, 92 (13) pp. 8750-8758.
[DOI][Pmid][serval:BIB_3A58DA889942]
Projecting single-cell transcriptomics data onto a reference T cell atlas to interpret immune responses
Andreatta Massimo, Corria-Osorio Jesus, Müller Sören, Cubas Rafael, Coukos George, Carmona Santiago J., 2020/06/24..
[URN][DOI][serval:BIB_2A40AFE9A2C6]
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/06/23. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][Pmid][serval:BIB_2DED61B64BB4]
 
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma.
Dheilly E., Battistello E., Katanayeva N., Sungalee S., Michaux J., Duns G., Wehrle S., Sordet-Dessimoz J., Mina M., Racle J. et al., 2020/05/11. Cancer cell, 37 (5) pp. 674-689.e12. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C0FB07A8B571]
 
Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft L.E., Odunsi K., Coukos G., 2020/05. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40 pp. 1-13. Peer-reviewed.
[DOI][Pmid][serval:BIB_71D55C2B15BF]
 
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G., Gainza P., Gray-Gaillard E., Cribioli E., Shui S., Kim S., Kwak M.J., Vollers S., Corria Osorio A.J., Reichenbach P. et al., 2020/04. Nature biotechnology, 38 (4) pp. 426-432. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EBAD72E3D84D]
 
Neoadjuvant immune-checkpoint blockade in resectable colon cancer.
Coukos G., 2020/04. Nature medicine, 26 (4) pp. 473-474. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EEF5ED613F7B]
miR-155 Overexpression in OT-1 CD8<sup>+</sup> T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.
Monnot G.C., Martinez-Usatorre A., Lanitis E., Lopes S.F., Cheng W.C., Ho P.C., Irving M., Coukos G., Donda A., Romero P., 2020/03/27. Molecular therapy oncolytics, 16 pp. 111-123. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_39DC24C5C585]
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L., Vitale I., Warren S., Adjemian S., Agostinis P., Martinez A.B., Chan T.A., Coukos G., Demaria S., Deutsch E. et al., 2020/03. Journal for immunotherapy of cancer, 8 (1) pp. e000337. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_56620B5927E2]
 
Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.
Solleder M., Guillaume P., Racle J., Michaux J., Pak H.S., Müller M., Coukos G., Bassani-Sternberg M., Gfeller D., 2020/02. Molecular & cellular proteomics, 19 (2) pp. 390-404. Peer-reviewed.
[DOI][Pmid][serval:BIB_0EBACC6764B1]
Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.
Germann M., Zangger N., Sauvain M.O., Sempoux C., Bowler A.D., Wirapati P., Kandalaft L.E., Delorenzi M., Tejpar S., Coukos G. et al., 2020/01/09. EMBO molecular medicine, 12 (1) pp. e10681. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F06A8D6CE8D2]
Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F., Semilietof A., Michaux J., Pak H.S., Coukos G., Müller M., Bassani-Sternberg M., 2020. Frontiers in immunology, 11 p. 1981. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E06D274ABF64]
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.
Vigano S., Bobisse S., Coukos G., Perreau M., Harari A., 2020. Frontiers in immunology, 11 p. 1350. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_19C82F6CB34E]
 
High-throughput identification of human antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells using soluble pMHC multimers.
Magnin M., Guillaume P., Coukos G., Harari A., Schmidt J., 2020. Methods in enzymology, 631 pp. 21-42. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD66E29F7790]
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Bianchi V., Harari A., Coukos G., 2020. Frontiers in immunology, 11 p. 1215. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B0551F2A3933]
2019
 
Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry.
Girotra M., Thierry A.C., Harari A., Coukos G., Naveiras O., Vannini N., 2019/12/26. Journal of visualized experiments 154. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE9A27B5B4E4]
Microfluidic device performing on flow study of serial cell-cell interactions of two cell populations.
Duchamp M., Dahoun T., Vaillier C., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2019/12/09. RSC advances, 9 (70) pp. 41066-41073. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E280C4A083E]
 
CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8<sup>+</sup> T-cell Responses.
Liu Y., Cuendet M.A., Goffin L., Šachl R., Cebecauer M., Cariolato L., Guillaume P., Reichenbach P., Irving M., Coukos G. et al., 2019/12/06. Journal of molecular biology, 431 (24) pp. 4941-4958. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7D824F910BFC]
 
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF9E566FB280]
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7C76EA90383]
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_313F7CD9FDBC]
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A., Griffiths B., Michaux J., Pak H.S., Stevenson B.J., Woolston A., Semiannikova M., Spain G., Barber L.J., Matthews N. et al., 2019/11/18. Journal for immunotherapy of cancer, 7 (1) p. 309. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7418AE3DFDA7]
 
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
Racle J., Michaux J., Rockinger G.A., Arnaud M., Bobisse S., Chong C., Guillaume P., Coukos G., Harari A., Jandus C. et al., 2019/11. Nature biotechnology, 37 (11) pp. 1283-1286. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9A8D08A5BC6]
 
The Romand Network of Oncology: bridging the gap of personalised oncology
Michielin O., Tsantoulis P., Homicsko K., Christinat Y., De Leval L., Bisig B., Missiaglia E., Zoete V., Krebs F., Fortin A. et al., 2019/10/18. Swiss Medical Weekly.
[serval:BIB_2A3947B3BCE2]
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC3C085DEA43]
 
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft L.E., Odunsi K., Coukos G., 2019/09/20. Journal of clinical oncology, 37 (27) pp. 2460-2471. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1583C45E6E7E]
Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery.
Fierle J.K., Abram-Saliba J., Brioschi M., deTiani M., Coukos G., Dunn S.M., 2019/09/06. Scientific reports, 9 (1) p. 12815. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FCB67A02E15F]
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8DDEE8DA1E]
 
Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.
Digklia A., Duran R., Homicsko K., Kandalaft L.E., Hocquelet A., Orcurto A., Coukos G., Denys A., 2019/09. Cardiovascular and interventional radiology, 42 (9) pp. 1221-1229. Peer-reviewed.
[DOI][Pmid][serval:BIB_13E5E5B29D1D]
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Bassani-Sternberg Michal, Digklia Antonia, Huber Florian, Wagner Dorothea, Sempoux Christine, Stevenson Brian J., Thierry Anne-Christine, Michaux Justine, Pak HuiSong, Racle Julien et al., 2019/08/08. Frontiers in Immunology, 10 p. 1832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0144F5D289B5]
 
F-18-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F575C6723CE]
Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
Herrera F.G., Irving M., Kandalaft L.E., Coukos G., 2019/08. The Lancet. Oncology, 20 (8) pp. e417-e433. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B919A825548B]
 
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C., Cachot A., Bobisse S., Arnaud M., Genolet R., Baumgaertner P., Speiser D.E., Sousa Alves P.M., Sandoval F., Adotévi O. et al., 2019/07/15. Clinical cancer research, 25 (14) pp. 4320-4331. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_99ED3D648751]
 
Médecine personnalisée. Bases de la formation interprofessionnelle prégraduée, postgraduée et continue des professionnels de la santé.
Colomer-Lahiguera Sara, 2019/07/08. dans Chapitre 10. La médecine personnalisée en oncologie, Académie Suisse des Sciences Médicales.
[serval:BIB_2F2397E20175]
Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.
Ebrahimi-Nik H., Michaux J., Corwin W.L., Keller G.L., Shcheglova T., Pak H., Coukos G., Baker B.M., Mandoiu I.I., Bassani-Sternberg M. et al., 2019/06/20. JCI insight, 5. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_77410C339277]
Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
Cicone F., Gnesin S., Denoël T., Stora T., van der Meulen N.P., Müller C., Vermeulen C., Benešová M., Köster U., Johnston K. et al., 2019/06/11. EJNMMI research, 9 (1) p. 53. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_22C26DF26A4B]
 
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95C8776874F3]
Effets indésirables des inhibiteurs de points de contrôle immunitaire : diagnostic et prise en charge [Side effects of immune checkpoint inhibitors: diagnosis and management]
Perrinjaquet C., Zaher M., Ferraro D.A., Comte D., Trueb L., Zimmermann S., Coukos G., Orcurto A., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1010-1016. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_542B193CD99A]
 
Tumor Landscapes: β-Catenin Drives Immune Desertification.
Dangaj D., Barras D., Coukos G., 2019/05/15. Clinical cancer research, 25 (10) pp. 2943-2945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7529A1E77088]
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Bol K.F., Schreibelt G., Rabold K., Wculek S.K., Schwarze J.K., Dzionek A., Teijeira A., Kandalaft L.E., Romero P., Coukos G. et al., 2019/04/18. Journal for immunotherapy of cancer, 7 (1) p. 109. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5E54765B4162]
 
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
Westergaard MCW, Andersen R., Chong C., Kjeldsen J.W., Pedersen M., Friese C., Hasselager T., Lajer H., Coukos G., Bassani-Sternberg M. et al., 2019/04..
[DOI][WoS][Pmid][serval:BIB_5C827EDF3F51]
 
Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection.
Zoete V., Coukos G., 2019/04/01. Cancer research, 79 (7) pp. 1299-1301. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B6A2460E1FCA]
The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.
Vannini N., Campos V., Girotra M., Trachsel V., Rojas-Sutterlin S., Tratwal J., Ragusa S., Stefanidis E., Ryu D., Rainer P.Y. et al., 2019/03/07. Cell stem cell, 24 (3) pp. 405-418.e7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C9755E6E69D]
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A5A6B3310C5]
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Wolf B., Zimmermann S., Arber C., Irving M., Trueb L., Coukos G., 2019/02. Drug safety, 42 (2) pp. 315-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_944ED4AF4291]
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
Westergaard MCW, Andersen R., Chong C., Kjeldsen J.W., Pedersen M., Friese C., Hasselager T., Lajer H., Coukos G., Bassani-Sternberg M. et al., 2019/02. British journal of cancer, 120 (4) pp. 424-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_031BC21D26AB]
 
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Maio M., Coukos G., Ferrone S., Fox B.A., Fridman W.H., Garcia P.L., Lahn M., Provendier O., Russo V., Rüttinger D. et al., 2019/01. Cancer immunology, immunotherapy, 68 (1) pp. 1-9. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C44CE339457D]
Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands.
Perez MAS, Bassani-Sternberg M., Coukos G., Gfeller D., Zoete V., 2019. Frontiers in immunology, 10 p. 2731. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA3DEC8F83B0]
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
[serval:BIB_B2FAEFC8A271]
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_42DB9145A8A7]
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S., Alatzoglou D., Irving M., Ménétrier-Caux C., Caux C., Romero P., Coukos G., 2019. Frontiers in immunology, 10 p. 925. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E661607B7DC8]
2018
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A., La Rosa S., Zurcher J.P., Zimmermann S., Spertini F., Coukos G., Obeid M., 2018/12/27. Journal for immunotherapy of cancer, 6 (1) p. 156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD7EE077DFE6]
 
The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.
Gfeller D., Guillaume P., Michaux J., Pak H.S., Daniel R.T., Racle J., Coukos G., Bassani-Sternberg M., 2018/12/15. Journal of immunology, 201 (12) pp. 3705-3716. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7CB706F40FEB]
Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.
Mylonas R., Beer I., Iseli C., Chong C., Pak H.S., Gfeller D., Coukos G., Xenarios I., Müller M., Bassani-Sternberg M., 2018/12. Molecular & cellular proteomics, 17 (12) pp. 2347-2357. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A79DB078A6D8]
 
Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.
Soler M., Li X., John-Herpin A., Schmidt J., Coukos G., Altug H., 2018/11/26. ACS sensors, 3 (11) pp. 2286-2295. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_03777D375057]
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J., Vicino A., Michielin O., Coukos G., Kuntzer T., Obeid M., 2018/10/22. Journal for immunotherapy of cancer, 6 (1) p. 110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E8CC11BAFBA]
Consensus guidelines for the use and interpretation of angiogenesis assays.
Nowak-Sliwinska P., Alitalo K., Allen E., Anisimov A., Aplin A.C., Auerbach R., Augustin H.G., Bates D.O., van Beijnum J.R., Bender RHF et al., 2018/08. Angiogenesis, 21 (3) pp. 425-532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0B60945B0B6F]
 
Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine Secretion.
Li X., Soler M., Szydzik C., Khoshmanesh K., Schmidt J., Coukos G., Mitchell A., Altug H., 2018/06. Small, 14 (26) pp. e1800698. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_40E1FE30E6D5]
The C-terminal extension landscape of naturally presented HLA-I ligands.
Guillaume P., Picaud S., Baumgaertner P., Montandon N., Schmidt J., Speiser D.E., Coukos G., Bassani-Sternberg M., Filippakopoulos P., Gfeller D., 2018/05/15. Proceedings of the National Academy of Sciences of the United States of America, 115 (20) pp. 5083-5088. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B915FD9A9BB]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
 
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE6933D4F057]
 
Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn.
Özdemir B.C., Coukos G., Wagner A.D., 2018/04/01. Annals of oncology, 29 (4) p. 1067. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_888420F74085]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.
Chong C., Marino F., Pak H., Racle J., Daniel R.T., Müller M., Gfeller D., Coukos G., Bassani-Sternberg M., 2018/03. Molecular & cellular proteomics, 17 (3) pp. 533-548. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A056F0253744]
 
Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X., Yang M., Chen X., Zhang X., Sukhadia S., Musolino N., Bao H., Chen T., Xu C., Wang Q. et al., 2018/02. Cancer immunology, immunotherapy, 67 (2) pp. 329-339. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EF0FC7F11707]
 
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y., Hu J., Wang Y., Peng X., Min J., Wang J., Matthaiou E., Cheng Y., Sun K., Tong X. et al., 2018/02. European journal of cancer, 90 pp. 111-121. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E091004637B]
 
Adoptive zelluläre Immuntherapie in der Schweiz. Onkologische Pflege 2 (2018).
Colomer-Lahiguera Sara, Debarge Patricia, Serena Andrea, Trueb Lionel, Eicher Manuela, Coukos George, 2018..
[serval:BIB_0708E4F6F8E0]
Correction to: CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi B.O., Dumauthioz N., Marti B., Zhang L., Lanitis E., Irving M., Schneider P., Mach J.P., Coukos G., Romero P. et al., 2018. Journal for Immunotherapy of Cancer, 6 (1) p. 92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE20F9B96389]
 
Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network.
Grass F., Martin D., Montemurro M., Mathevet P., Wolfer A., Coukos G., Demartines N., Hübner M., 2018. Chemotherapy, 63 (3) pp. 143-147. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4174AA4D6600]
2017
 
Cancer immunotherapy full speed ahead.
Melero I., Navarro B., Teijeira A., Coukos G., 2017/12/01. Annals of oncology, 28 (suppl_12) pp. xii1-xii2. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DA57E8E33449]
 
Mechanisms regulating T-cell infiltration and activity in solid tumors.
Lanitis E., Dangaj D., Irving M., Coukos G., 2017/12/01. Annals of oncology, 28 (suppl_12) pp. xii18-xii32. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE2398AAD635]
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S., Chevalier M.F., Martinez-Usatorre A., Gomez-Cadena A., Salomé B., Lecciso M., Salvestrini V., Verdeil G., Racle J., Papayannidis C. et al., 2017/09/19. Nature communications, 8 (1) p. 593. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_40D92F523196]
 
Label-free identification of activated T lymphocytes through tridimensional microsensors on chip.
Rollo E., Tenaglia E., Genolet R., Bianchi E., Harari A., Coukos G., Guiducci C., 2017/08/15. Biosensors & bioelectronics, 94 pp. 193-199. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8DDCB6B9A58E]
 
In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.
Schmidt J., Guillaume P., Dojcinovic D., Karbach J., Coukos G., Luescher I., 2017/07/14. The Journal of biological chemistry, 292 (28) pp. 11840-11849. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5AC2BD6D841F]
The ovarian cancer oncobiome.
Banerjee S., Tian T., Wei Z., Shih N., Feldman M.D., Alwine J.C., Coukos G., Robertson E.S., 2017/05/30. Oncotarget, 8 (22) pp. 36225-36245. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E109B279F39B]
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk B.J., Brady M.F., Aghajanian C., Lankes H.A., Rizack T., Leach J., Fowler J.M., Higgins R., Hanjani P., Morgan M. et al., 2017/05/01. Annals of oncology, 28 (5) pp. 996-1004. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B4FD453E2DFC]
 
Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Byrne A.T., Alférez D.G., Amant F., Annibali D., Arribas J., Biankin A.V., Bruna A., Budinská E., Caldas C., Chang D.K. et al., 2017/04. Nature reviews. Cancer, 17 (4) pp. 254-268. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DAE66A3080A8]
'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M., Gfeller D., Coukos G., Bassani-Sternberg M., 2017. Frontiers in Immunology, 8 p. 1367. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A4DBE7C295A9]
Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.
Bassani-Sternberg M., Chong C., Guillaume P., Solleder M., Pak H., Gannon P.O., Kandalaft L.E., Coukos G., Gfeller D., 2017. PLoS Computational Biology, 13 (8) pp. e1005725. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F969601F848]
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
Irving M., Vuillefroy de Silly R., Scholten K., Dilek N., Coukos G., 2017. Frontiers in immunology, 8 p. 267. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E326B4204C76]
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.
Facciabene A., De Sanctis F., Pierini S., Reis E.S., Balint K., Facciponte J., Rueter J., Kagabu M., Magotti P., Lanitis E. et al., 2017. Oncoimmunology, 6 (9) pp. e1326442. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_69B217E99597]
 
Radiotherapy combination opportunities leveraging immunity for the next oncology practice.
Herrera F.G., Bourhis J., Coukos G., 2017/01. CA: a cancer journal for clinicians, 67 (1) pp. 65-85. Peer-reviewed.
[DOI][Pmid][serval:BIB_558CD2425591]
 
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.
Merkle P.S., Irving M., Hongjian S., Ferber M., Jørgensen TJD, Scholten K., Luescher I., Coukos G., Zoete V., Cuendet M.A. et al., 2017. Biochemistry, 56 (30) pp. 3945-3961. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7CF39E44F352]
TIE-2 expressing monocytes in human cancers.
Turrini R., Pabois A., Xenarios I., Coukos G., Delaloye J.F., Doucey M.A., 2017. Oncoimmunology, 6 (4) pp. e1303585. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D0E518DFF81]
2016
 
Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors.
Homicsko K., Duraiswamy J., Doucey M.A., Coukos G., 2016/12/01. Cancer research, 76 (23) pp. 6765-6767. Peer-reviewed.
[DOI][Pmid][serval:BIB_611A58A2720E]
 
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
Röhrig U.F., Majjigapu S.R., Caldelari D., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P., Zoete V. et al., 2016/09/01. Bioorganic & medicinal chemistry letters, 26 (17) pp. 4330-4333. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9DF2682ECDFF]
 
Mass spectrometry-based antigen discovery for cancer immunotherapy.
Bassani-Sternberg M., Coukos G., 2016/08. Current opinion in immunology, 41 pp. 9-17. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B7C4824CBB21]
 
Traitement des cancers: n'oublions pas les enjeux humains et sociaux des progrès actuels et à venir!
Dietrich P.Y., Coukos G., Aapro M., 2016/05/18. Revue medicale suisse, 12 (519) pp. 963-964. Peer-reviewed.
[Pmid][serval:BIB_9ECEE908E0D8]
 
The Human Vaccines Project: A roadmap for cancer vaccine development.
Romero P., Banchereau J., Bhardwaj N., Cockett M., Disis M.L., Dranoff G., Gilboa E., Hammond S.A., Hershberg R., Korman A.J. et al., 2016/04/13. Science translational medicine, 8 (334) pp. 334ps9. Peer-reviewed.
[DOI][Pmid][serval:BIB_8E2A78076655]
 
Opportunities in immunotherapy of ovarian cancer.
Coukos G., Tanyi J., Kandalaft L.E., 2016/04. Annals of oncology, 27 Suppl 1 pp. i11-i15. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_659109342A6F]
 
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets R., Donnadieu E., Chouaib S., Coukos G., 2016/02. Seminars in immunology, 28 (1) pp. 10-21. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D12442A44DA8]
Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.
Salerno E.P., Bedognetti D., Mauldin I.S., Deacon D.H., Shea S.M., Pinczewski J., Obeid J.M., Coukos G., Wang E., Gajewski T.F. et al., 2016. Oncoimmunology, 5 (12) pp. e1240857. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7BCD9F561820]
Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis.
Crespo I., Götz L., Liechti R., Coukos G., Doucey M.A., Xenarios I., 2016. NPJ systems biology and applications, 2 p. 16037. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5114129C390E]
 
Neoantigen-based cancer immunotherapy.
Bobisse S., Foukas P.G., Coukos G., Harari A., 2016. Annals of Translational Medicine, 4 (14) p. 262. Peer-reviewed.
[DOI][Pmid][serval:BIB_F74C06B31066]
 
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.
Zsiros E., Dangaj D., June C.H., Kandalaft L.E., Coukos G., 2016. Oncoimmunology, 5 (5) pp. e1062210. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1852FDBECBFC]
 
Personalized approaches to active immunotherapy in cancer
Ophir Eran, Bobisse Sara, Coukos George, Harari Alexandre, Kandalaft Lana E., 2016/01. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1865 (1) pp. 72-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01C8158A4FDC]
 
Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy.
Zhao A., Tohidkia M.R., Siegel D.L., Coukos G., Omidi Y., 2016. Critical Reviews In Biotechnology, 36 (2) pp. 276-289. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_025704A90C14]
 
Principes de la thérapie cellulaire par transfert adoptif à base de Tumor Infiltrating Lymphocytes [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
Martins F., Orcurto A., Michielin O., Coukos G., 2016. Revue Médicale Suisse, 12 (519) pp. 989-993. Peer-reviewed.
[Pmid][serval:BIB_4503E564FA67]
TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer.
Bron S., Henry L., Faes-Van't Hull E., Turrini R., Vanhecke D., Guex N., Ifticene-Treboux A., Marina Iancu E., Semilietof A., Rufer N. et al., 2016. Oncoimmunology, 5 (2) pp. e1073882. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C97ACD28497]
2015
 
Immuno-Oncology
Michielin Olivier, Coukos George, 2015/09/09. Progress in Tumor Research, 42, S. Karger AG.
[DOI][serval:BIB_3BABB0481053]
 
An ultra-sensitive impedimetric immunosensor for detection of the serum oncomarker CA-125 in ovarian cancer patients.
Johari-Ahar M., Rashidi M.R., Barar J., Aghaie M., Mohammadnejad D., Ramazani A., Karami P., Coukos G., Omidi Y., 2015. Nanoscale, 7 (8) pp. 3768-3779. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A3D5DD2E8958]
Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches.
Guex N., Crespo I., Bron S., Ifticene-Treboux A., Faes-Van't Hull E., Kharoubi S., Liechti R., Werffeli P., Ibberson M., Majo F. et al., 2015. PLoS Computational Biology, 11 (3) pp. e1004050. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC95917CF5CA]
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L., Ladoire S., Coukos G., Ghiringhelli F., 2015. Annals of Oncology, 26 (9) pp. 1813-1823. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B0FEEA6CE1BB]
 
Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.
Yan X., Hu Z., Feng Y., Hu X., Yuan J., Zhao S.D., Zhang Y., Yang L., Shan W., He Q. et al., 2015. Cancer Cell, 28 (4) pp. 529-540. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C1048CB1FB57]
 
Consensus nomenclature for CD8 + T cell phenotypes in cancer
Apetoh L., Smyth M.J., Drake C.G., Abastado J.P., Apte R.N., Ayyoub M., Blay J.Y., Bonneville M., Butterfield L.H., Caignard A. et al., 2015. Oncoimmunology, 4 (4) pp. e998538. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1DB47249851]
 
Erratum to: Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.
Barar J., Kafil V., Majd M.H., Barzegari A., Khani S., Johari-Ahar M., Asgari D., Coukos G., Omidi Y., 2015..
[DOI][WoS][Pmid][serval:BIB_070748C72E26]
 
High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.
Chevalier M.F., Bobisse S., Costa-Nunes C., Cesson V., Jichlinski P., Speiser D.E., Harari A., Coukos G., Romero P., Nardelli-Haefliger D. et al., 2015. Oncoimmunology, 4 (10) pp. e1029702. Peer-reviewed.
[DOI][Pmid][serval:BIB_FC441F50334F]
Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.
Barar J., Kafil V., Majd M.H., Barzegari A., Khani S., Johari-Ahar M., Asgari D., Coukos G., Omidi Y., 2015. Journal of Nanobiotechnology, 13 (1) p. 26. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D3C3F085EE13]
Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.
Karapetsas A., Giannakakis A., Dangaj D., Lanitis E., Kynigopoulos S., Lambropoulou M., Tanyi J.L., Galanis A., Kakolyris S., Trypsianis G. et al., 2015. Biomed Research International, 2015 p. 712438. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_082FCA6C4652]
 
Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang C.L., Balint K., Coukos G., Kandalaft L.E., 2015. Expert Opinion On Biological Therapy, 15 (4) pp. 569-582. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05E27D099B4D]
 
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell D.D., Böhm S., Ahmed A.A., Aspuria P.J., Bast R.C., Beral V., Berek J.S., Birrer M.J., Blagden S., Bookman M.A. et al., 2015. Nature Reviews. Cancer, 15 (11) pp. 668-679. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DD8901DF61B3]
T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression.
Santoro S.P., Kim S., Motz G.T., Alatzoglou D., Li C., Irving M., Powell D.J., Coukos G., 2015. Cancer Immunology Research, 3 (1) pp. 68-84. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00550F80C313]
 
Targeting Programmed Cell Death 1 in Ovarian Cancer.
Homicsko K., Coukos G., 2015. Journal of Clinical Oncology, 33 (34) pp. 3987-3989. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A88FF3F32E5C]
Targeting the tumor vasculature to enhance T cell activity.
Lanitis E., Irving M., Coukos G., 2015. Current Opinion in Immunology, 33 pp. 55-63. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_266C11B75B8F]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University